Phase III typically includes further exploring which aspect in a broader population?

• A. Evaluate adverse event rates in single center
• B. Limit scope to one geographic region
• C. Focus solely on pharmacokinetics
• D. Further explore the dose-response relationship or use in wider populations

Answer: (D)

In Phase III, the goal is to confirm how well the treatment works and to understand its safety across a broad and diverse patient population, which helps define the real-world dose and generalizability. That means you actively examine how the drug’s effects vary with different doses and in people from various backgrounds and settings. This broader, dose-ranging and population-wide assessment is what Phase III emphasizes.

The other options reflect activities more typical of earlier phases or narrower scopes. Investigating adverse event rates at a single center is more characteristic of early-phase, limited-scope studies; limiting the trial to one geographic region undermines the generalizability that Phase III aims to establish; and focusing only on pharmacokinetics is a hallmark of early-phase PK studies, not Phase III.